Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Employees - 128,
CEO - Dr. Krishna Vaddi D.V.M., Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 104.75M
Altman ZScore(max is 10): -4.44, Piotroski Score(max is 10): 3, Working Capital: $134163000, Total Assets: $197220000, Retained Earnings: $-554832000, EBIT: -143262000, Total Liabilities: $40789000, Revenue: $6424000
AryaFin Target Price - $0.13 - Current Price $1.30 - Analyst Target Price $3.33
| Ticker | PRLD |
| Index | RUT |
| Curent Price | 1.30 |
| Change | 46.40% |
| Market Cap | 104.75M |
| Average Volume | 425.48K |
| Income | -131.52M |
| Sales | 3.00M |
| Book Value/Share | 2.84 |
| Cash/Share | 1.91 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 128 |
| Moving Avg 20days | 34.25% |
| Moving Avg 50days | 5.79% |
| Moving Avg 200days | -62.81% |
| Shares Outstanding | 42.18M |
| Earnings Date | Nov 06 AMC |
| Inst. Ownership | 35.27% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 34.92 |
| Price/Book | 0.46 |
| Price/Cash | 0.68 |
| Price/FCF | - |
| Quick Ratio | 7.04 |
| Current Ratio | 7.04 |
| Debt/Equity | 0.12 |
| Return on Assets | -57.72% |
| Return on Equity | -66.64% |
| Return on Investment | -76.53% |
| Gross Margin | 46.20% |
| Ops Margin | -4775.40% |
| Profit Margin | -4383.90% |
| RSI | 63.10 |
| BETA(β) | 1.40 |
| From 52week Low | 63.19% |
| From 52week High | -80.88% |
| EPS | -1.90 |
| EPS next Year | -1.50 |
| EPS next Qtr | -0.47 |
| EPS this Year | 12.13% |
| EPS next 5 Year | 30.10% |
| EPS past 5 Year | -43.14% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 12.47% |
| Sales Y/Y | - |
| EPS Q/Q | 5.99% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | 8.90% |
| ATR(14) | 0.14 |
| Perf Week | 62.50% |
| Perf Month | 35.18% |
| Perf Quarter | -45.15% |
| Perf Year | -67.25% |
| Perf YTD | -69.56% |
| Target Price | 3.33 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer